Notice of Results and Stroke Clinical Trial Update

RNS Number : 4025H

ReNeuron Group plc

27 May 2011

 



 

 

PRESS RELEASE

 

Notification of date of preliminary results and update on stroke clinical trial

Guildford, UK, 27 May 2011: ReNeuron Group plc (LSE: RENE.L) is pleased to announce the completion of dosing of the first cohort of patients in the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients.  The PISCES study (Pilot Investigation of Stem Cells in Stroke) is the world's first fully regulated clinical trial of a neural stem cell therapy for disabled stroke patients.   The PISCES clinical trial is being conducted in Scotland at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.

In line with the update given in March, the last of the three patients in this dose cohort was treated with ReN001 earlier this month and was safely discharged from hospital two days later.  In this Phase I single administration dose escalation study, ReNeuron's ReN001 stem cell therapy is being administered to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition. The aim of the study is to test the safety and tolerability of the treatment in progressive doses whilst assessing longer term efficacy measures for the design of future clinical trials with ReN001.

The Company will provide a further update on the PISCES clinical trial in its 2011 preliminary results statement.  The Group will report its preliminary results for the year ended 31 March 2011 on Thursday 30 June 2011.  A briefing for analysts will be held at 10:00am (BST) on the day at the offices of Buchanan Communications, 107 Cheapside, London EC2V 5DN.

Enquiries:

Michael Hunt, Chief Executive Officer - ReNeuron            [phone]

Dr John Sinden, Chief Scientific Officer - ReNeuron

Lisa Baderoon, Mark Court, Isabel Podda                        [phone]

Buchanan Communications                                      

Antony Legge, Oliver Rigby                                                  [phone]

Daniel Stewart & Company plc                              

James Gallagher, Stephen Waterman                               [phone]

Matrix Corporate Capital LLP                                

About ReNeuron

ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in early clinical development.  ReNeuron's ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell^®products for use in academic and commercial research.  The Company's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate.  A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

MSCPGUMPAUPGGRQ